Skip to main content

Table 3 Identifying incident major IHD or cerebrovascular eventsa

From: Identification of major cardiovascular events in patients with diabetes using primary care data

Drug (at least 1 prescription) TP FP TN FN Sens (95 % CI) Spec (95 % CI) PPV (95 % CI) NPV (95 % CI)
GP/Hosp IHD/cerebrovascular eventsb
 Vitamin K antagonists 16 324 14689 569 3 (2–4) 98 (98–98) 5 (3–8) 96 (96–97)
 Platelet aggregation inhibitors 147 495 11654 167 47 (41–53) 96 (96–96) 23 (20–26) 99 (98–99)
 Nitrates 73 308 15196 470 13 (11–17) 98 (98–98) 19 (15–23) 97 (97–97)
 Vitamin K antagonists/Platelet aggregation inhibitors 129 626 10230 106 55 (48–61) 94 (94–95) 17 (14–20) 99 (99–99)
 Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 132 650 10088 98 57 (51–64) 94 (93–94) 17 (14–20) 99 (99–99)
Hosp IHD/cerebrovascular eventsc
 Vitamin K antagonists 13 331 14944 310 4 (2–7) 98 (98–98) 4 (2–6) 98 (98–98)
 Platelet aggregation inhibitors 107 545 11744 68 61 (53–68) 96 (95–96) 16 (14–19) 99 (99–100)
 Nitrates 59 330 15431 227 21 (16–26) 98 (98–98) 15 (12–19) 99 (98–99)
 Vitamin K antagonists/Platelet aggregation inhibitors 92 673 10282 44 68 (59–75) 94 (93–94) 12 (10–15) 100 (99–100)
 Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 94 697 10137 39 71 (62–78) 94 (93–94) 12 (10–14) 100 (99–100)
  1. Abbreviations: IHD ischaemic heart disease, GP general practitioner, Hosp hospitalization, TP true positive, FP false positive, TN true negative, FN false negative, Sens sensitivity, Spec specificity, PPV positive predictive value, NPV negative predictive value
  2. aPrescriptions are considered to be in agreement with actual events if being prescribed between 30 days before to 90 days after the date of the major IHD or cerebrovascular event
  3. bUsing hospitalizations or general practitioners diagnoses as reference standard
  4. cUsing only hospitalizations as reference standard